To this end, we evaluated EO771-scramble-treated (mesenchymal-like) and EO771-miR-200c-mimic-treated (epithelial-like) whole cell vaccines for stimulation of antitumor immunity as measured by (1) cytotoxic response against EO771-B7.1 ± miR-200c target cells and (2) protection from EO771 tumor growth (Figure 3A). This evidence concerns the gene CD80 and neoplasm.